Lack of association of IDH1, IDH2, and DNMT3A mutations with outcome in older patients with AML treated with hypomethylating agents

Samankaltaisia teoksia

• Case series of AML patients receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations
  Tekijä: Benton, Chris, et al.
  Julkaistu: (2013)
• Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
  Tekijä: DiNardo, Courtney D., et al.
  Julkaistu: (2015)
• Prognostic Significance of Alterations in IDH Enzyme Isoforms in Patients With AML Treated With High Dose Cytarabine and Idarubicin
  Tekijä: Ravandi, Farhad, et al.
  Julkaistu: (2011)
• Clofarabine plus low-dose cytarabine is as effective as and less toxic than intensive chemotherapy in elderly AML patients
  Tekijä: Takahashi, Koichi, et al.
  Julkaistu: (2015)
• Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents
  Tekijä: Alfonso, Ana, et al.
  Julkaistu: (2017)